Literature DB >> 16916939

Stimulation of steroid receptor coactivator-3 (SRC-3) gene overexpression by a positive regulatory loop of E2F1 and SRC-3.

Paola Mussi1, Chundong Yu, Bert W O'Malley, Jianming Xu.   

Abstract

Steroid receptor coactivator 3 (SRC-3, amplified in breast cancer 1, or ACTR) is a transcriptional coactivator for nuclear receptors and certain other transcription factors such as E2F1. SRC-3 is overexpressed in breast cancers, and its overexpression is sufficient to cause mammary carcinomas in vivo. However, the mechanisms controlling endogenous SRC-3 overexpression are unknown. In this study, we identified the first exon and analyzed the 5' regulatory sequence of the SRC-3 gene. We found three evolutionarily conserved regions (ECRs) in the 5' SRC-3 regulatory sequence, and ECR2 makes a major contribution to the SRC-3 promoter activity. The ECR2 region (bp -250/+350) contains several specificity protein 1 (Sp1) binding sites and two E2F1 binding sites. We show that E2F1 can significantly activate the ECR2 promoter activity in a dose-dependent manner. Furthermore, overexpression of E2F1 significantly increases the promoter activity of the endogenous SRC-3 gene and boosts SRC-3 expression in vivo. Conversely, knockdown of E2F1 reduces SRC-3 expression. We demonstrate that the mechanism of E2F1 activity on SRC-3 promoter is independent of the E2F binding sites but relies on the Sp1 element located at bp +150/+160. Sp1, E2F1, and SRC-3 are specifically recruited to this Sp1 site and the interaction between E2F1 and Sp1 is essential to modulate SRC-3 expression. Moreover, SRC-3 coactivates E2F1 activity and thereby additively stimulates a further increase in SRC-3 expression in vivo. These results suggest that in cells with hyperactive E2F1, such as the case encountered in breast cancer cells, there is a positive feedback regulatory loop consisting of E2F1 and SRC-3 to maintain high levels of SRC-3 and E2F1 activity, which may partially interpret the oncogenic role of SRC-3 overexpression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16916939     DOI: 10.1210/me.2005-0522

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  36 in total

1.  The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression.

Authors:  Ankur Sharma; Wen-Shuz Yeow; Adam Ertel; Ilsa Coleman; Nigel Clegg; Chellappagounder Thangavel; Colm Morrissey; Xiaotun Zhang; Clay E S Comstock; Agnieszka K Witkiewicz; Leonard Gomella; Erik S Knudsen; Peter S Nelson; Karen E Knudsen
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

2.  Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1.

Authors:  Ying Wang; David M Lonard; Yang Yu; Dar-Chone Chow; Timothy G Palzkill; Jin Wang; Ruogu Qi; Alexander J Matzuk; Xianzhou Song; Franck Madoux; Peter Hodder; Peter Chase; Patrick R Griffin; Suoling Zhou; Lan Liao; Jianming Xu; Bert W O'Malley
Journal:  Cancer Res       Date:  2014-01-03       Impact factor: 12.701

3.  Research resource: loss of the steroid receptor coactivators confers neurobehavioral consequences.

Authors:  Erin Stashi; Lei Wang; Shailaja K Mani; Brian York; Bert W O'Malley
Journal:  Mol Endocrinol       Date:  2013-08-08

4.  The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer.

Authors:  Jean C-Y Tien; Zhaoliang Liu; Lan Liao; Fen Wang; Yixiang Xu; Ye-Lin Wu; Niya Zhou; Michael Ittmann; Jianming Xu
Journal:  Cancer Res       Date:  2013-05-06       Impact factor: 12.701

5.  ERK3 promotes endothelial cell functions by upregulating SRC-3/SP1-mediated VEGFR2 expression.

Authors:  Wei Wang; Ka Bian; Sreeram Vallabhaneni; Bin Zhang; Ray-Chang Wu; Bert W O'Malley; Weiwen Long
Journal:  J Cell Physiol       Date:  2014-10       Impact factor: 6.384

6.  Steroid receptor coactivator-3 regulates glucose metabolism in bladder cancer cells through coactivation of hypoxia inducible factor 1α.

Authors:  Wei Zhao; Cunjie Chang; Yangyan Cui; Xiaozhi Zhao; Jun Yang; Lan Shen; Ji Zhou; Zhibo Hou; Zhen Zhang; Changxiao Ye; Donald Hasenmayer; Robert Perkins; Xiaojing Huang; Xin Yao; Like Yu; Ruimin Huang; Dianzheng Zhang; Hongqian Guo; Jun Yan
Journal:  J Biol Chem       Date:  2014-02-28       Impact factor: 5.157

7.  Steroid receptor co-activator-3 promotes osteosarcoma progression through up-regulation of FoxM1.

Authors:  Shuo Geng; Xiaoyu Wang; Xiaoyan Xu; Hepeng Zhang; Yan Ma; Yunqi Zhang; Baoxin Li; Zhenggang Bi; Chenglin Yang
Journal:  Tumour Biol       Date:  2013-11-27

8.  Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice.

Authors:  Arthur C-K Chung; Suoling Zhou; Lan Liao; Jean Ching-Yi Tien; Norman M Greenberg; Jianming Xu
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

9.  Identification of SRC3/AIB1 as a preferred coactivator for hormone-activated androgen receptor.

Authors:  X Edward Zhou; Kelly M Suino-Powell; Jun Li; Yuanzheng He; Jeffrey P Mackeigan; Karsten Melcher; Eu-Leong Yong; H Eric Xu
Journal:  J Biol Chem       Date:  2010-01-19       Impact factor: 5.157

10.  Nuclear receptor coactivator-6 attenuates uterine estrogen sensitivity to permit embryo implantation.

Authors:  Jun Kawagoe; Qingtian Li; Paola Mussi; Lan Liao; John P Lydon; Francesco J DeMayo; Jianming Xu
Journal:  Dev Cell       Date:  2012-10-16       Impact factor: 12.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.